FDA tells CBD companies: Stop making ‘unfounded’ claims about CBD products


The Food and Drug Administration has sent warning letters to companies it says are making “egregious and unfounded” claims about the benefits of products made with CBD, a non-psychoactive compound found in cannabis, the agency said Tuesday.

Scott Gottlieb, the agency’s commissioner, also said he was “concerned” that several national pharmacy chains have begun selling CBD products and warned that the FDA will be contacting those chains to “remind them of FDA obligations.” Walgreens and CVS both recently announced that they will begin selling products with CBD.

The warnings about CBD marketing come as the FDA also tries to construct a regulatory framework for products infused with CBD, which can be derived from legal hemp plants. Hemp, a type of cannabis plant containing extremely low amounts of THC, the psychoactive compound responsible for marijuana highs, was legalized last year under the 2018 Farm Bill.

Ga naar Bron